Elite Pharma Had a Bidder. It Said No, Then Rallied 56%.
The board shelved a takeout it had spent a year campaigning for, flipped its priorities to a NASDAQ uplist, and pinned the whole equity story on 2027 filings
ELTP · Earnings Call · 2026-11-13
The $40 million that isn't the same $40 million
Elite posted $40.1 million of revenue for the September quarter against $36.3 million a year earlier — a 10% gain. The CFO, Carter Ward, wants you to read that number differently than last time: “our top line is back to the $40 million level, but it's a different $40 million” — Carter Ward, Chief Financial Officer · 2026-11-13. The difference is composition. The $40 million quarter of June 2025 was essentially a Lisdex market artifact — generic Vyvanse at pre-correction prices. That correction has run its course; what replaced it is breadth: the ADHD product family (mixed amphetamine salts IR and ER) plus the opioid addiction and pain lines. Concentration risk is genuinely lower, which is worth something. But the arithmetic underneath the narrative is grimmer. This is the slowest growth rate in the recent record: the June 2026 quarter came in at $41 million, up 27% year over year, and this quarter grew 10%. Gross margin, 40% versus 39% a year ago, got there by falling from 54% — the price erosion from new Lisdex competitors is now visible in the margin line rather than the revenue line. And management is candid that the biggest product is constrained by the DEA, not by demand: “Quota is an issue for Lisdex. We are not getting it as fast as we would like to... it's like almost hand to mouth.” — Nasrat Hakim, Chairman and Chief Executive Officer · 2026-11-13 That is a structural quota-and-plant capacity ceiling on the one product that has carried the P&L.The buyer showed up. The board said not yet.
The most consequential thing on this call had nothing to do with the third quarter. Nasrat Hakim disclosed that roughly three weeks ago his bankers conveyed a verbal offer from one of the parties that had already visited and diligenced the company.Read that twice. The company set a premium hurdle, the bidder cleared the hurdle, and the board declined anyway — citing a share price that had moved lower since the ask was framed, not the offer itself. The interested party is being invited back in 2027 after a few bioequivalence studies, an approvable letter on the anticoagulant, and some facility progress. This is a straight reversal of stated priority, and the prior calls show it. In July 2025 Hakim was unambiguous: “Our top priority is merger and acquisition, a buyout. If that does not work, then NASDAQ is an option.” — Nasrat Hakim, Chairman and Chief Executive Officer · 2025-07-01 He even gave a clock on the process: “We will decide if we will enact Phase 2 within the coming 3 to 4 months.” — Nasrat Hakim, Chairman and Chief Executive Officer · 2025-07-01 Seventeen months later, Phase 2 produced a bid and was shelved. The stated hierarchy has inverted: NASDAQ — with its uplist to NASDAQ target of March 2027 and NASDAQ listing application in calendar Q1 — is now the plan, and M&A is the option. The market is not obviously aggrieved. The tape shows a stock that fell 31% over seventeen weeks to mid-November, then ripped 56% in five sessions — with a 52% nine-day surge in the trailing 90-day window and only a 7.3% drawdown from the July 16 peak of $0.40. A rejection of a takeout offer is usually a sell signal for a $345 million microcap. Here it was a rally. Either investors are pricing the "2027 re-rating" story or they simply read the disclosure as leverage. That is a genuine disagreement worth watching.The Board discussed the proposal and voted to pass on that opportunity. The Board decided to shelf the negotiations for now... even though they gave us what we wanted, the price changed so drastically that, that's not really what we want anymore.